Pioneering the expanded human proteome to reveal a universe of new medicines.
- Tweets 97
- Following 57
- Followers 153
- Likes 9
Featured in @NatureBiotech: CEO John Lepore, MD, explains how novel proteins beyond the annotated proteome could open new paths for medicines. ProFound is building the largest atlas of novel proteins to help advance first-in-class therapies. nature.com/articles/s41587-0…
2
7
2,510
Last week, our CEO, John Lepore, MD, spoke with @FierceBiotech's Darren Incorvaia about a new investment from the @gatesfoundation to create new solutions for women’s health.
Read the full article here: fiercebiotech.com/biotech/fl…
1
24
Today we announced an investment from @gatesfoundation to discover new medicines for preeclampsia/eclampsia. Using our ProFoundry™ Platform & AI, we will explore the expanded proteome to understand the biology affecting mothers & babies at risk. Details: profoundtx.com/news-and-even…
3
3,155
Proud to share that ProFound is a nominee for the 2026 #PrixGalien USA Awards for Best Startup. This recognition from The Galien Foundation reflects our team's work bringing first-in-class therapies to patients. Grateful to be named alongside such impressive peers.
𝗣𝗿𝗶𝘅 𝗚𝗮𝗹𝗶𝗲𝗻 𝟮𝟬𝟮𝟲 𝗻𝗼𝗺𝗶𝗻𝗲𝗲𝘀 𝗼𝗳𝗳𝗶𝗰𝗶𝗮𝗹 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗱!
#PrixGalien USA nominees for Best Digital Health Solution, Best MedTech, Best Incubators, Accelerators and Equity, & Best Startup have been announced: prn.to/4ci9pOk
65
Today, we announced the appointment of Ainslie Little, Ph.D. as Chief Operating Officer. She will oversee daily operations and lead strategic execution as we scale the ProFoundry Platform and advance a growing therapeutic pipeline. Full release: profoundtx.com/news-and-even…
90
We’re strengthening our leadership with the appointments of Tom Chittenden as CTO to lead the evolution of the ProFoundry™ Platform's AI, computational, and genetics capabilities & Laurel Ostrom as CHRO to build our organizational foundation and culture: bit.ly/48V52X6
1
196
Thrilled to partner with @GSK to advance new #COPD and #IPF therapies, powered by novel proteins discovered by our ProFoundry™ Platform. We look forward to driving innovation in respiratory care. Read more: bit.ly/488VtDA
1
159
Addressing complex disease biology calls for innovative solutions. In cardiovascular disease, we're leveraging our ProFoundry™ Platform to reveal a new universe of drug targets and, in collaboration with Novartis, develop transformative therapies: bit.ly/41cpVKj
1
127
Understanding industry expectations and mitigating risk are key to the success of bioplatforms. Our CEO, John Lepore, MD, joined @FishburnSimone on the @BioCentury Show to share how we remain resilient in an evolving landscape: bit.ly/4mmmWaL
97
We’re thrilled to welcome Rebecca Mosher, MD, to ProFound as our new SVP, Oncology Research! A seasoned leader in translational medicine, Rebecca brings deep precision oncology expertise that will support our mission to advance programs powered by the expanded proteome.
88
Meet David Stone, our new Head of Cardiovascular, Metabolic, and Neuroscience Diseases at ProFound. With 25+ years in genetics, screening & target discovery, David brings the vision and experience to advance transformative therapies for patients. Welcome to the team, David!
1
1
71
We’re thrilled to welcome Tom Chittenden as CTO at ProFound. A pioneer in AI-driven biomedicine, his 25+ years leading data science & platform innovation will drive our efforts to decode the #expandedproteome via the ProFoundry™ Atlas.
Learn more: bit.ly/4bDe0aZ
1
815
For decades, we believed only ~2% of DNA encodes proteins, but recent research shows ~80% is transcribed into RNA. Our ProFoundry™ Platform is uncovering novel proteins & defining their functions to fuel development of first-in-class medicines. More here: bit.ly/4aV1Kl
1
48
We’ve teamed up with @Novartis to tackle #CardiovascularDisease. By combining our ProFoundry™ Platform with their deep expertise, we’re unlocking new biology and accelerating the path to breakthrough therapies. More in this @endpts piece @ByLizC:
bit.ly/45J9R5S
1
86
We’re proud to partner with @Novartis to discover & develop novel medicines for #cardiovascular disease using our ProFoundry™ Platform. Together, we aim to illuminate new biology & accelerate the path to transformative cardiovascular therapies. Read more: bit.ly/3IhoDXC
5
1,603
Join our CEO, John Lepore, MD, as he takes the stage at #BIO2025 alongside fellow industry leaders to explore how Nobel Prize-winning science can translate into real world therapies to tackle pressing health challenges. Learn more about the panel: bit.ly/4kCJt2d
1
69
#NationalDNADay marks the completion of the #HumanGenomeProject. At ProFound, we’re building on that legacy—uncovering novel proteins encoded by previously undefined regions of the genome with vast therapeutic potential. More here: bit.ly/4aV1Klr
1
54
Our CEO, John Lepore, is moderating a panel discussion at the @LongwoodLeaders #MiamiCEO meeting where panelists will share expert insights on emerging trends on partnerships and the future of deal-making in biopharma. Details: bit.ly/425tPFL #longwoodhealthcareleaders
1
84
What if many ‘non-coding’ RNAs could produce functional proteins? This question fueled development of the ProFoundry™ Platform to rapidly discover and implicate novel proteins in disease. Learn more here: bit.ly/4bDe0aZ
73
Listen to our CEO, John Lepore, on @SanoGenetics' #TheGeneticsPodcast with @patrick_j_short to learn more about ProFound’s strategy for identifying the most promising drug or drug targets from the #ExpandedProteome. 🎧 bit.ly/3Y06y5s
2
143